Prostate Cancer: Markers (MP60): Moderated Poster 60: Monday, September 13, 2021
MP60-17 PREDICTIVE CONTRIBUTION OF A MOLECULAR SIGNATURE TO THE CAPRA PROGNOSTIC CLASSIFICATION OF PROSTATE CANCERS BEFORE RADICAL PROSTATECTOMY
INTRODUCTION AND OBJECTIVE:
The CAPRA score is a clinic-biological score that allows to estimate the risk of Prostate Cancer (PCa) recurrence after curative treatment. Recent preliminary studies have evidenced prognostic molecular subgroups in PCa. Our objective was to assess the PCa recurrence risk after radical prostatectomy (RP) using molecular data at the time of biopsies.
Each patient that underwent RP from 2008 to 2011 issued from the PROGENE cohort were included. Following data were collected: age, CAPRA score, D’Amico score, ISUP biopsy grade, MRI findings, recurrence after RP. RNA extraction from biopsies was performed as well as a quantitative study of the expression of 37 genes using the Nanostring nCounter©multiplex system. The primary endpoint was the occurrence of biological recurrence. A predictive molecular score (NANO) was calculated for each patient and evaluated through ROC curves.
Overall, 121 patients were included. Mean age at diagnosis was 62 years (SD=5.8), 12 patients (9.9%) had a family history of PCa and 70 (60%) had a preoperative CAPRA score <3. Mean follow-up was 7.5 years (SD=3) and 25 patients had a biological relapse (20.7%). Exploratory analysis revealed 3 distinct Nano groups. Two patients in the Nano 0 group relapsed (5.4%) while 12 patients (50%) in the Nano 2 group had a recurrence. Kaplan Meier curve (fig. 1) showed a significant difference in recurrence-free survival in favor of the Nano 0 group (10.8 years) compared to the Nano 2 group (8.2 years, p=0.001). The area under the ROC curve for the recurrence prediction was 0.81 for Nano score and 0.72 for the CAPRA score.
The use of a molecular score based on the expression of 37 biomarkers on prostate biopsies seems to be efficient for estimating biological PCa recurrence after RP. The moderate cost and the small number of biomarkers could make it a tool that could be deployed on a larger scale. Externa validation is needed.
Source of Funding:
None© 2021 by American Urological Association Education and Research, Inc.